Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
No idea as to what is driving this up, but a 4.41% increase in share price on 116k volume (total number of share is in the region of 1.5 billion) is extremely intriguing :)
Thanks LumpedOn for sharing, much appreciated :)
Re Research report - I have rung the number listed on the company website - it went to Finance, but they have promised to ask Communications to contact me re the research report. I did some homework on this over the weekend and added another 30K today at 62.5p.I expect that the results on 28 June will give an impetus to the share price and in terms of the longer term this is way undervalued. Good luck all :)
Tipped in the latest Shares mag as well. Strong IP, multiple revenue streams, multiple geographies, tightly held with good institutional support, Inve acquisition in Dec 2015 likely to make this transformational in terms of revenue and profitability. I have opened a position with 50k buys today. Good luck all :)
RNS on 26.05.2016...by transferring ARC shares into ISAs for both himself and his wife, the CE is indicating a strong and confident outlook for the company and ensuring that they will enjoy tax free dividends and tax free capital gains. Wonder at what share price / other financial measure, the options of the senior team are vested ?
RNS Number : 5314Y Ideagen PLC 18 May 2016 18 May 2016 Ideagen PLC ("Ideagen," "the Company" or the "Group") Pre-Close Trading Update Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2016 ahead of the announcement of its full year results. The Board is pleased to report that trading for the year was robust and results to 30 April 2016 are expected to be in line with market expectations. The Group delivered strong organic revenue growth of 10 per cent., and a full year contribution from Gael which was acquired in January 2015. The Group expects to report revenue of approximately GBP21.9 million (FY2015: GBP14.4 million), an increase of 52 per cent. resulting in adjusted EBITDA* of approximately GBP6.3 million (FY2015: GBP4.0 million), an increase of 57 per cent. This represents the Group's seventh consecutive year of revenue and EBITDA* growth. In addition, the Group expects to show a significant increase in adjusted EPS** which continues to be an important financial metric for the Group. Cash generation remained strong, particularly in the second half of the year, and net cash at 30 April 2016 was GBP6.3 million (31 October 2015: GBP5.4 million), after paying GBP1.7 million of deferred consideration, principally for the Gael acquisition, and GBP0.3 million in dividends. The Group continues to maintain a debt-free balance sheet. The strong trading results have been driven predominately by healthy demand across the Group's Governance, Risk and Compliance ("GRC") markets, including the manufacturing, life sciences, aviation and rail verticals. The Board is also encouraged by the success of the Group's newly launched SaaS platform, Enlighten, which is allowing the Group to win larger contracts and grow high visibility, subscription-based revenue. As a result, the Board remains confident in the long term growth prospects for the Group. David Hornsby, Chief Executive, commented: "The Group has once again delivered another year of high quality earnings growth, demonstrating the strength of our business model, the quality of our products and the talent of our employees. The Group has significant contracted work in progress, a growing recurring revenue base and a healthy pipeline of new business, which leaves me optimistic about the continued growth opportunities for the Group." *Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and exceptional items. **Adjusted diluted earnings per share
Fantastic news on landing another big contract :) RNS Number : 9402W SimiGon Limited 03 May 2016 Tuesday May 3, 2016 SimiGon Ltd ("SimiGon" or "the Company") SimiGon awarded 5.5 year contract worth $7.9 million for civilian aviation training solutions in the Far East SimiGon continues to expend into the civilian market SimiGon (LSE: SIM), a global leader in providing simulation solutions, is pleased to announce that it has signed an exclusive five-and-a-half-year contract (the "Contract Period") to deliver SIMbox based training solutions to a leading provider of training solutions for the civilian aviation industries in the Far East (the "Contract"). Under the terms of the Contract, SimiGon will be paid $7.9 million to license its SIMbox software over the Contract Period, with a minimum of $1.4 million per year starting this year. The revenue contribution from this contract was already factored into management's expectations for the year ended 31 December 2016. It also will contribute to improved revenue visibility for FY 2017 and beyond. This is another major contract outside of the defense industry and it will further expand the Company's growth strategy to diversify its product offering and increase its addressable market. The Contract underlines SimiGon's potential to access a much larger addressable market and has the potential to enable SimiGon to expand further into other civilian aviation industries with similar opportunities. SimiGon President & CEO, Ami Vizer, said: "This Contract is part of SimiGon's strategy to focus on long-term, high value, stable license contracts which provide better revenue and profit visibility rather than on single lump sum license sales. We are excited to be awarded this Contract which strengthens our position in the civilian aviation sector; a sector which we strongly believe has significant growth potential. We are delighted to be working alongside a leading regional provider of training solutions to the civilian aviation industries and who have a clear vision of how our technology can leverage their current and future businesses". Enquiries: SimiGon Ltd Ami Vizer, Chief Executive Tel: +1 (407) Officer 951 5548 Efi Manea, Chief Financial Officer www.simigon.com finnCap (NOMAD & Broker) Stuart Andrews / Scott Mathieson Tel: +44 (0) 20 (corporate finance) 7220 0500 This information is provided by RNS The company news service from the London Stock Exchange END
This is yet another fantastic announcement - certainly sounds like we have moved up a gear :) RNS New contract wins in life science sector New revenue generated from life science vertical in excess of GBP1 million in current financial year Ideagen plc (AIM:IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to announce a number of recent contract wins in the life science industry, bringing the total customer contribution from this industry alone to more than GBP1 million in revenue since the start of the financial year. This makes life science one of the fastest growing verticals this year for Ideagen within the Governance, Risk and Compliance ("GRC") market. During the year, Ideagen has secured in excess of GBP1 million in new software and service revenue from both new customers and expanded engagements with existing customers in the life science vertical. The Group has signed up 27 new customers, including a leading in-vitro diagnostics and pharmaceutical company, a UK science-based university and a global pharmaceutical therapy development company. Ideagen's electronic quality management system, Q-Pulse, is the most widely used solution from the product suite for customers in the life science industry. During the period, Ideagen agreed a strategic partnership with DataVita Ltd, operator of the UK's first life sciences and healthcare compliant datacentre. This partnership will enable the Company to offer the Q-Pulse solution via the DataVita validated platform, opening up further opportunities with life science organisations looking for a hosted solution. David Hornsby, Chief Executive Officer of Ideagen, said: "We continue to see strong demand for our product suite across all of our vertical markets, including transport, finance and complex manufacturing, however demand within the life science industry has been particularly strong this year. While life sciences alone still represents a small proportion of overall revenue, we are pleased with the traction we are making in this industry and see this as an important sector from which to grow further as we roll out new products and upgrades, as well as launch the DataVita hosted Q-Pulse solution. "To break through the GBP1 million barrier with healthy existing and new business contracts is testament to the strength of our products and to the expertise of our team in what is a rapidly growing industry."
Very strong growth and increased profitability :) RNS Number : 4662T 30 March 2016 Learning Technologies Group plc (AIM: LTG) Final Results 2015 Learning Technologies Group plc ("LTG" or the "Group"), the global integrated e-learning technology and services business, is pleased to announce its audited results for the year ended 31 December 2015, which show strong growth in revenue and margins. Financial highlights: -- Revenue increased to GBP19.9 million (2014: GBP14.9 million) - up 33% -- Adjusted EBITDA more than doubled to GBP4.3 million (2014: GBP2.1 million) - up 107% -- Significantly improved adjusted EBITDA margin of 21% (2014: 14%) - up 50% -- Adjusted diluted earnings per share of 0.756p (2014: 0.375p per share) - up 102% -- Proposed dividend for the full year of 0.15p per share (2014: 0.10p) - up 50% -- Balance sheet strengthened further - GBP7.3 million cash and no debt Operational highlights: -- Acquisition of Eukleia to LTG portfolio in July 2015 for initial consideration of GBP8.3 million: - adds governance, risk and compliance expertise and specialist financial services sector offering - business now fully integrated and operating to plan -- Landmark contract win delivered in a strategic alliance with KPMG UK LLP for UK Civil Service: - delivering blended learning for over 400,000 staff over next three years - demonstrating credibility and scale of LTG's offering and capabilities -- Post year end acquisition of Rustici and investment in Watershed: - places LTG at the heart of global e-learning interoperability standards - ability to ascertain the impact and effectiveness of learning programmes Andrew Brode, Chairman of LTG, said: "The last 18 months have been transformational for the Group. Our strategy of creating a group of market-leading businesses providing global, complementary services in the fast growing learning technologies sector is rapidly taking shape." Jonathan Satchell, Chief Executive Officer of LTG, said: "We have established a strong platform on which we can build and the Group is delivering to plan. I believe that LTG is very well placed to achieve a prominent position in a highly fragmented, growing market, currently estimated to be worth GBP140 billion. We see the ability to measure the impact of learning as the next major disruption to the e-learning industry. LTG's acquisition of Rustici and investment in Watershed in January 2016 places us at the vanguard of this crucial and exciting change. We view the future with confidence."
RNS yesterday confirming cancellation of the share premium account and registration of this with Companies House. This clears the legal hurdle that prevented payment of dividend so far. With Directors holding about 25-26%, I would think they would like to reward themselves and share holders with a handsome dividend given that we are sitting on a £1.8m cash pile. The Chief Executive and his wife have transferred 9m ARC shares into their ISA as per another RNS. Market has not twigged that there is a lot of background activity and yet to join the dots. In an era where news and data is widely available, successful investing comes from being able to interpret and synthesise these into meaningful information. Good luck all :) Good luck all :)
All in public domain.... Pros: Revenues going up. Profits going up. Sticky blue chip customers, rolling contracts. Directors skin in the game. Likely to be dividend paying soon. £1.8m cash pile and growing. No debt. Cons: Tiny market cap, ill liquid, very conservatively managed, very poor news flow. If you get hold of the Finncap research note that may help inform your decision making.
Hi Kums, I think that we will make progress till the mid 0.40s atleast in the next few months. This could be fundamentally sustained in terms of market cap. Not sure we will get CTP like returns though...unless we have a take over attempt or some fantastic dividend or a slew of major contracts. One can never tell and we can always hope :)
No RNS as yet re legal proceedings.... ARC did well yesterday given the state of the markets. ECB QE and Anthony Cross increasing his holding to 14.3% may offer a bit more impetus to the share price though I am mentally prepared for a flat day or bit of retrace given the spike yesterday. I reckon about 50% is closely held....and there may be several holders holding low single percent holdings (non declarable)...so free float is tight. I reckon we can achieve a stable 0.04 to 0.45p range in the next few months based on what we have seen yesterday. If dividends are announced, this could do more I think. The current low share price makes it a tempting buy - more bang for buck when you can buy in quantity. Pleased that virtually all LTHS are very comfortably in profit now :) Good luck all !
Debt free, conservatively run and managed, low profile Profit making, recurrent and predictable revenue stream £1.8m circa cash as per recent half yearly accounts, low employee headcount Bank if International Settlements, Bank of England, Central Banks, HM Treasury Debt Management, Tier 1 Banks (Citibank, Deutsche Bank as far as I know) and top global investment banks,financial instis as customers Global market, aiming for wider geographic footprint Market cap very undervalued Share price just above currrent EPS High Barriers to entry, scalable business with no major capex, niche segment with one major competitor (Contex) ARC products better value for money and ARC pursuing market of "conflicted customers disillusioned with bigger players" and want value for money New products being developed which will increase scope of addressable market High customer retention, with 3 year rolling contracts, unless cancelled Directors hold about 25% of equity One of UK Top Fund Managers Anthony Cross holds about 14% - recently added another 19m shares Legal process underway to cancel share premium account to enable payment of dividends in due course Share consolidation likely at some point, which will open the stock to fund managers Increased required for transparency and audit trail following LIBOR and other financial scandals Potential takeover target due to low market cap May use available funds for acquisition, organic growth market pretty big Recent Finncap new target of 0.30p - initial research note out in July 2015, target updated recently, but comfortably broken Appears to meet Liontrust Economic Criteria for investment Good luck :)
Cheers Kums :) Delighted you are in and not too late I think - I am bullish about this very conservative little company.
Yes....nice to see :) All in good time as ARC is grossly undervalued IMHO. Wait till dividends are announced, then the market will finally wake up.
Yes noticeably high volumes including a 500k buy at .32p News imminent regarding permission of share premium cancellation I would think....maybe even by the end of the week !
Looks like the Court Hearing regarding the cancellation of the ARC share premium account may have been heard on 29.02.2016 before Registrar Briggs. It was scheduled for 10:30 Source: axxp://page2rss.com/0e5e804bc63dcf005bc90674096a44f2/7973815_7975051 Case Number: CR - 2015 - 008769 Don't know how long it will take for the decision to be formally announced. Once this legal formality is completed, the Board could decide on the payment of a dividend in due course. £1.8m cash at hand and growing. No debt :) Good luck all :)
Revenues up by 9%, profits up by 78%, eps is not far off the cmp, no debt and £1.8m cash pile. The increased revenue has virtually gone straight to the bottom line. Good to see 0.3p paid for 15k shares..... Dividends can't be too far behind :)
Steady buying over the last 10 days or so....share price ticking up with regular frequency following any decent size trade. If there is further institutional interest, the small free float will be under real pressure. Under the radar for most investors it appears given the lack of BB discussion. Often a good sign but share price action will draw in the thundering herd :)